S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Lithium Overdose: Can These 2 Lithium Stocks Recover in 2024?
'Civil War’ continues box-office campaign at No. 1
Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?
Intuitive Surgical Leads the Robotic Surgery Movement
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Stock market today: World shares shrug off Wall St blues as investors eye corporate earnings
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Lithium Overdose: Can These 2 Lithium Stocks Recover in 2024?
'Civil War’ continues box-office campaign at No. 1
Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?
Intuitive Surgical Leads the Robotic Surgery Movement
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Stock market today: World shares shrug off Wall St blues as investors eye corporate earnings
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Lithium Overdose: Can These 2 Lithium Stocks Recover in 2024?
'Civil War’ continues box-office campaign at No. 1
Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?
Intuitive Surgical Leads the Robotic Surgery Movement
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Stock market today: World shares shrug off Wall St blues as investors eye corporate earnings
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Lithium Overdose: Can These 2 Lithium Stocks Recover in 2024?
'Civil War’ continues box-office campaign at No. 1
Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?
Intuitive Surgical Leads the Robotic Surgery Movement
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Stock market today: World shares shrug off Wall St blues as investors eye corporate earnings
OTCMKTS:CYDY

CytoDyn (CYDY) Stock Price, News & Analysis

$0.16
+0.00 (+2.72%)
(As of 04/19/2024 08:51 PM ET)
Today's Range
$0.15
$0.16
50-Day Range
$0.15
$0.26
52-Week Range
$0.13
$0.42
Volume
662,900 shs
Average Volume
2.74 million shs
Market Capitalization
$153.89 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
CYDY stock logo

About CytoDyn Stock (OTCMKTS:CYDY)

CytoDyn Inc., a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer. Its leronlimab is currently under phase 2 development for the treatment of NASH, HIV- NASH, and solid tumors, as well as under pre-clinical development for the treatment of HIV-PrEP and HIV-Cure. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.

CYDY Stock Price History

CYDY Stock News Headlines

CytoDyn Says FDA Lifts Hold On Leronlimab
This Apple-like Innovator is Revolutionizing Healthcare
AI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.
CytoDyn Announces FDA Has Lifted Clinical Hold
CytoDyn Inc CYDY
This Apple-like Innovator is Revolutionizing Healthcare
AI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.
Investors file another lawsuit against CytoDyn
CytoDyn Announces Webcast to Provide Company Update
CytoDyn Appoints Jacob Lalezari M.D. as Interim CEO
CytoDyn (OTC: CYDY)
See More Headlines
Receive CYDY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CytoDyn and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
4/15/2024
Today
4/22/2024
Fiscal Year End
5/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
OTCMKTS:CYDY
Previous Symbol
NASDAQ:CYDY
CUSIP
23283M101
Fax
N/A
Employees
12
Year Founded
N/A

Profitability

Net Income
$-79,820,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$270,000.00
Book Value
($0.12) per share

Miscellaneous

Free Float
985,823,000
Market Cap
$153.89 million
Optionable
Not Optionable
Beta
0.17
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

  • Dr. Cyrus Arman M.B.A. (Age 42)
    Ph.D., Senior Vice President of Business Operations
    Comp: $451.17k
  • Dr. Jacob P. Lalezari M.D. (Age 64)
    CEO & Member of Scientific Advisory Board
  • Mr. Mitchell Cohen (Age 67)
    Interim Chief Financial Officer
  • Mr. Tyler Blok (Age 36)
    Executive Vice President of Legal Affairs & Secretary
  • Dr. Scott Hansen Ph.D.
    Head of Research & Basic Science
  • Mr. Joseph Meidling
    Executive Director of Clinical Operations
  • Ms. Cristina De Leon
    Investors

CYDY Stock Analysis - Frequently Asked Questions

How have CYDY shares performed in 2024?

CytoDyn's stock was trading at $0.1950 at the beginning of 2024. Since then, CYDY shares have decreased by 20.5% and is now trading at $0.1550.
View the best growth stocks for 2024 here
.

Are investors shorting CytoDyn?

CytoDyn saw a drop in short interest in March. As of March 31st, there was short interest totaling 4,680,600 shares, a drop of 8.4% from the March 15th total of 5,107,100 shares. Based on an average trading volume of 2,871,500 shares, the short-interest ratio is currently 1.6 days.
View CytoDyn's Short Interest
.

How were CytoDyn's earnings last quarter?

CytoDyn Inc. (OTCMKTS:CYDY) released its quarterly earnings data on Monday, April, 15th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter.

What other stocks do shareholders of CytoDyn own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CytoDyn investors own include Inovio Pharmaceuticals (INO), Novavax (NVAX), NVIDIA (NVDA), Johnson & Johnson (JNJ), Gilead Sciences (GILD), Vaxart (VXRT), Nokia Oyj (NOK), Pfizer (PFE), Sorrento Therapeutics (SRNE) and Moderna (MRNA).

How do I buy shares of CytoDyn?

Shares of CYDY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:CYDY) was last updated on 4/22/2024 by MarketBeat.com Staff

From Our Partners